EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient

Michael Fink, Marion Pollheimer, Alexander Kirsch, Alexander R Rosenkranz, Kathrin Eller, Max Schuller

Frontiers in Medicine · 31.03.2026 · 13

DOI: 10.3389/fmed.2026.1702864 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 31.03.2026. Verfasst von Michael Fink und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombotic microangiopathy (TMA) after kidney transplantation presents a significant diagnostic and therapeutic challenge. Complement-mediated thrombotic microangiopathy (CM-TMA), caused by dysregulation of the alternative complement pathway, is frequently associated with predisposing variants in complement-regulatory genes but typically requires additional triggers for clinical manifestation. Ravulizumab, a long-acting terminal complement inhibitor, has demonstrated efficacy in native kidney disease, but data in transplant recipients remain limited. We present a 75-year-old kidney transplant recipient in whom previously unrecognized CM-TMA was triggered by COVID-19 infection and successfully treated with ravulizumab. This case underscores the importance of considering CM-TMA in the differential diagnosis of posttransplant TMA and in patients with end-stage kidney disease of uncertain origin, demonstrating that age alone should not preclude diagnostic consideration, and supports ravulizumab as an effective therapeutic option in this setting.

Schlagwörter

Stichwörter der Autor:innen

COVID-19atypical HUScomplement-mediated thrombotic microangiopathyfactor H (FH)kidney transplantationravulizumabthrombotic microangiopathy (TMA)

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Institute of Pathology, Medical University of Graz, Graz, Austria.

Zitieren

APA

Fink, M., Pollheimer, M., Kirsch, A., Rosenkranz, A. R., Eller, K., & Schuller, M. (2026). Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1702864

Vancouver

Fink M, Pollheimer M, Kirsch A, Rosenkranz AR, Eller K, Schuller M. Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1702864

BibTeX
@article{Fink2026,
  author = {Fink, Michael and Pollheimer, Marion and Kirsch, Alexander and Rosenkranz, Alexander R and Eller, Kathrin and Schuller, Max},
  title = {Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1702864}
}
Kostenlos starten →